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ABSTRACT. Despite recent advances, a general method for the synthesis of α-carbonyl-α’-
(hetero)aryl sulfoxonium ylides is needed to benefit more greatly from the potential safety 
advantages offered by these compounds over the parent diazo compounds. Herein, we report the 
palladium-catalyzed cross-coupling of aryl bromides and triflates with α-carbonyl sulfoxonium 
ylides. We also report the use of this method for the modification of an active pharmaceutical 
ingredient and to the synthesis of a key precursor of antagonists of the neurokinin-1 receptor. In 
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addition, the mechanism of the reaction was inferred from several observations. Thus, the 
oxidative addition complex [(XPhos)PhPdBr] and its dimer were observed by 31P{1H} NMR and 
these complexes were shown to be catalytically and kinetically competent. Moreover, a complex 
resulting from the transmetallation of [(XPhos)ArPdBr] (Ar = p-CF3-C6H4) with a model 
sulfoxonium ylide was observed by mass spectrometry. Finally, the partial rate law suggests that 





Metal-catalyzed reactions of sulfoxonium ylides have recently enjoyed a renaissance1–5 that is 
encouraged by the potential utility of these methods for the multi-kilogram synthesis of drug 
candidates.6 Hence, intensive efforts have been recently directed to the development of catalytic 
methods for the formation of carbon-carbon7–28 and carbon-heteroatom29–36 bonds from these 
ylides. Moreover, comparison of the energy released in differential scanning calorimetry studies 
clearly demonstrates the potential safety advantages offered by α-carbonyl sulfoxonium ylides 
over the parent diazo compounds.7,8 
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Scheme 1. Synthetic utility of α-carbonyl-α’-(hetero)aryl sulfoxonium ylides and their 
preparation by palladium-catalyzed cross-coupling. 
 
Significantly, most of these methods involve the use of α-carbonyl sulfoxonium ylides that have 
only one substituent attached to the ylide carbon atom. A notable exception is the use of a bis-
substituted α-carbonyl-α’-aryl sulfoxonium ylide in the synthesis of an advanced pyrrole precursor 
of atorvastatin (Scheme 1a),34 an anti-cholesterol top-selling drug.  
However, the preparation of bis-substituted α-carbonyl-α’-(hetero)aryl sulfoxonium ylides 
remains challenging and therefore limits their wider application in synthesis despite their 
significant potential utility. Thus, the sulfoxonium ylide depicted in Scheme 1a was prepared by 
the decomposition of an α-carbonyl-α’-aryl diazo compound in the presence of rhodium(II) acetate 
under harsh conditions that are not compatible with the high thermal potential of diazo 
compounds.31,37,38 Although simple α-carbonyl-α’-(hetero)aryl sulfoxonium ylides can be 
prepared by reaction of arynes and α-carbonyl sulfoxonium ylides,39 this approach does not enable 
easy structural variations of the (hetero)aryl group  because of the necessary multi-step synthesis 
of the aryne precursors and the potential regioselectivity issues typical of many intermolecular 
reactions of unsymmetrical arynes.40 Moreover, although iodoniums can serve as precursors of 
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sulfoxonium ylides,41 the reported method is not suitable for the synthesis of ylides bearing both 
an electron-acceptor substituent and a (hetero)aryl group. As an alternative, one could consider a 
two-step sequence beginning with the nucleophilic aromatic substitution of reactive heterocycles 
with dimethylsulfoxonium methylide followed by an acylation,42 but it cannot be applied to the 
introduction of simple aryl halides of decreased electrophilic character. Finally, the palladium-
catalyzed carbonylative arylation of α-carbonyl sulfoxonium ylides has been described with aryl 
iodides, but it has not been described with less expensive aryl bromides or for the preparation of 
sulfoxonium ylides that bear only one electron-withdrawing group.43 Accordingly, a general 
method for the preparation of α-carbonyl-α’-(hetero)aryl sulfoxonium ylides from easily available 
precursors remains needed. 
Herein, we now report the palladium-catalyzed cross-coupling of aryl bromides and triflates with 
α-carbonyl sulfoxonium ylides (Scheme 1b). The synthetic utility of the method is illustrated with 
the modification of an active pharmaceutical ingredient and by the synthesis of a key precursor of 
antagonists of the neurokinin-1 receptor. A mechanism is proposed on the basis of control 
experiments. 
RESULTS AND DISCUSSION 
Optimization and scope of the reaction. During our study of the palladium-catalyzed cross-
coupling of α-ester sulfoxonium ylides and aryl bromides,7 initial tests of the reactivity of α-ketone 
sulfoxonium ylide 1 led us to believe that no reaction occurred because ylides 1 and 2 were not 
distinguishable by thin layer chromatography. However, examination of the crude mixture by 1H 
NMR confirmed that modest conversion was achieved (Table 1, entry 1). It is noteworthy that α-
ketone sulfoxonium ylides are far less reactive than the corresponding esters in this palladium-
catalyzed reaction. Nevertheless, by switching the ligand to XPhos and changing the stoichiometry 
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(entry 2) and concentration (entry 3) of the reaction, we managed to reach full conversion of ylide 
1 and isolate pure 2 in good yield. Moreover, it is remarkable that sulfoxonium ylide 1 was 
recovered unchanged when mixed with either iodobenzene or bromobenzene and treated under the 
conditions that catalyze the cross-coupling of aryl iodides with α-diazo ketones.44 Sulfoxonium 
ylides and diazo compounds have therefore a very distinct reactivity in palladium-catalyzed 
reactions. 
Table 1. Optimization of the reaction conditions 
 
a Yield determined from 1H NMR of the crude mixture. b Isolated as two fractions, one of them 
containing 8% of recovered starting material 1. c Yield of isolated pure product. Cy = cyclohexyl. 
Scope of the reaction. Although the reaction conditions were at this stage not completely 
optimized with respect to the stoichiometry of reactants, we were eager to rapidly establish their 
generality. We found that varying the sulfoxonium fragment was well tolerated as illustrated with 
functionalized alkyl groups bearing for example an indole, a pyrrole, an ether, and Boc-protected 
primary and secondary amines (Figure 1, 3–7), whereby the yields remained high throughout. 
Whereas primary (3–6) and secondary (7, 8) alkyl groups were compatible, attempts for which the 
R group was a tertiary alkyl group (e.g. adamantyl) led to no conversion. On the other hand, 
sulfoxonium ylides bearing electron-poor (9) or electron-rich (10) aryl groups, as well as 
heteroaryls (11 and 12) groups, underwent the cross-coupling in high yields. Similarly, the aryl 
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bromides could be varied to give cross-coupled products 13–20 (Figure 2), although para-
bromoanisole gave 15 in a lower yield due to the decomposition of the product under the reaction 
conditions. Thus, in that case, an optimal result was obtained by stopping the reaction after 2 hours. 
Moreover, the coupling of heteroaryl bromides gave 21 and 22, and that of aryl triflates gave 
examples 23 and 24. Finally, it is noteworthy that this protocol afforded formyl derivatives 25 and 
26 in excellent yields. 
 
Figure 1. Scope of α-ketone sulfoxonium ylides. Yields of pure isolated products from the 
reactions of aryl bromide (1 mmol, 2.5 equiv), α-ketone sulfoxonium ylides (0.4 mmol, 1.0 equiv), 
Cs2CO3 (0.44 mmol, 1.1 equiv) in MeCN (0.8 mL). 
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Figure 2. Scope of (hetero)aryl bromides. Yields of pure isolated products from the reactions of 
aryl bromides (1 mmol, 2.5 equiv), α-carbonyl sulfoxonium ylides (0.4 mmol, 1.0 equiv), Cs2CO3 
(0.44 mmol, 1.1 equiv) in MeCN (0.8 mL). a 1H NMR yield. b From triflate. 
Importantly, further optimization of the reaction conditions enabled us to decrease the loading of 
aryl bromide and of XPhos. Decreasing the amount of aryl bromide is particularly relevant for the 
late-stage modification of more precious material, as for example the antihistamine drug 
bromazine.45 Cross-coupling product 27 could thus be obtained in 79% yield by using only 1.1 
equivalent of bromazine and 11 mol % of XPhos (Scheme 2). Moreover, reducing the excess of 
aryl bromide and XPhos is also relevant for gram-scale applications, as for example the reaction 
of sulfoxonium ylide 28 with bromobenzene that gave 29 without decrease of the yield (Scheme 
3). By using an iridium catalyst,31 this intermediate could then be converted in good yield into 
piperidinone 30, a common precursor of L-733,060 and CP-99,994, two drugs developed as 
antagonists of the neurokinin-1 receptor.46,47 It is noteworthy that the cyclization of 29 to give 30 
is the first of its kind on a bis-substituted α-ketone-α’-(hetero)aryl sulfoxonium ylide. 
Scheme 2. Late-stage modification of bromazine. 
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Scheme 3. Gram-scale synthesis of a drug precursor. 
 
Study of the mechanism. To gain an insight into the mechanism of this reaction, we started our 
study by preparing the known oxidative addition complex 31.48 We observed that this complex 
was catalytically competent in the cross-coupling of 32 with bromobenzene (Scheme 4), and its 
use actually led to a higher yield of product 33 as compared to what was obtained under the 
conditions used to establish the scope described in figures 1 and 2. Importantly, the kinetic 
competence of 31 was also established in the conversion of 32 into 33 and no difference of initial 
rate was observed when compared to that obtained by using the combination of Pd2(dba)3 and 
XPhos. 
Scheme 4. Catalytic competence of oxidative addition complex 31. 
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Moreover, complex 31 was also observed by 31P NMR of the crude mixture resulting from the 
coupling of ylide 34 and bromobenzene into product 13 (Figure 3). Thus, besides resonances for 
XPhos and its oxide, we observed only a broad resonance at  = 27.2 ppm and a sharper one at  
= 55.6 ppm (Figure S1, Supporting Information) in an approximately equimolar ratio, which we 
attribute to the monomer solvate complex [31•MeCN] and the solvent-free dimer 
[(XPhos)PhPdBr]2, respectively. The attribution of these resonances is in a good agreement with 
the findings recently reported by Hii and co-workers in their study of related mono-phosphines 
complexes.49 
 
Figure 3. Observation of a dimer of the oxidative addition intermediate by 31P NMR and 
possible structures of transmetalation intermediates detected by mass spectrometry. Ar = p-
CF3C6H4. 
Having established that the oxidative addition complexes [(XPhos)ArPdBr] are catalytically and 
kinetically competent, we attempted to isolate a transmetalation complex that would result from 
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the reaction of 31 and sulfoxonium ylides, but this endeavor remained unsuccessful. However, the 
mass spectrum of the crude supernatant of the reaction between ylide 34 and p-CF3C6H4Br, carried 
out under the catalytic conditions described in figure 2, showed minor peaks corresponding to a 
transmetalation complex with the correct isotope distribution, which would correspond to either 
35 ([35]+) or 36 ([36 + H]+) (Figure 4). The formation of such intermediates would be consistent 
with an earlier report of a palladium complex resulting from the stoichiometric transmetalation of 
Pd(II) salts with an α-ketone sulfoxonium ylide.50 Besides these minor peaks, the most abundant 
peaks we could identity were those of the product 18 ([18 + H]+) and of a fragment of the oxidative 
addition complex 37 ([37 – Br]+), as well as those of XPhos and its oxide (Figure S2, Supporting 
Information). The interpretation of this data was confirmed by the independent synthesis of 
complex 37 that was characterized by X-ray crystallography as a dimer in the solid state (Figure 
4). Analysis of pure 37 by mass spectrometry gave the same molecular peaks corresponding to the 
fragment [37– Br]+. 
 
Figure 4. Crystal structure of oxidative addition complex 37 in the solid state. 
Scheme 5. Proposed mechanism. 
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In view of the data collected in our study, we propose a mechanism (Scheme 5), by which rapid 
ligand exchange between dba and XPhos would generate an active catalyst (L = dba or MeCN).51 
Then, oxidative addition would give intermediate I that is in equilibrium with an off-cycle inactive 
dimer II, which is the resting state of the catalyst. We propose that I would undergo transmetalation 
to III upon reaction with the ylide, which would be followed by deprotonation to give IV, whose 
reductive elimination would regenerate the active catalyst and liberate the observed cross-coupling 
products. 
Further support for the proposed mechanism was obtained by determining the rate law of the 
reaction conducted between model substrates p-CF3C6H4Br and sulfoxonium ylide 34. Varying 
the initial concentrations of aryl bromide (0.30 – 1.25 M), ylide 34 (0.1 – 1.5 M), XPhos (0.06 – 
0.50 M), and Pd2(dba)3 (0.006 – 0.038 M). We found that the initial rate (ratei) obeyed the equation 
ratei = kobs[ylide]
0.6[Pdtot]
0.5, whereas the order in aryl bromide and ligand was zero. These results 
confirmed several aspects of the mechanism of this reaction. First, the half-order in palladium is 
consistent with an equilibrium between inactive dimer II and the kinetically and catalytically 
competent oxidative addition intermediate I.52 Second, the partial order in ylide observed in the 
rate law also suggests that the transmetalation is in the rate-determining zone of the catalytic 
cycle.53 Third, the Lineweaver-Burk plots of the reciprocal of the initial rate as a function of the 
reciprocal of the individual concentration of ylide (Figure 5) gave a good linear correlation with 
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non-zero y intercept, which confirmed that one molecule of ylide is involved in the 
transmetalation. Fourth, although Cs2CO3 is not soluble under the reaction conditions, we observed 
a linear increase of the initial rate when increasing the amount of base from 0.44 to 2.0 equivalents 
(See supporting information). This effect suggests that the deprotonation step should also be 
included in the rate-determining zone, even if the order dependence in the concentration of base 
could not be rigorously established.54 
 
Figure 5. Lineweaver-Burk plots of the reaction of model sulfoxonium ylide 34 and p-
CF3C6H4Br. 1/ratei = 56.8 ± 4.4 + (27.9 ± 0.9)/[34] (R
2 = 0.99). Data from duplicate experiments. 
Error bars omitted for clarity. 
Overall, these results highlight a remarkable contrast between α-ketone sulfoxonium ylides and α-
diazoketones. Hence, our findings indicate that the transmetalation and deprotonation steps of the 
palladium-catalyzed cross-couplings of aryl bromides with α-carbonyl sulfoxonium ylides are rate-
determining, whereas theoretical study of the palladium-catalyzed cross-coupling of α-diazo 
ketones and aryl iodides suggested these two steps occurred without kinetic barrier.44 As 
mentioned previously, it is noteworthy that the model α-carbonyl sulfoxonium ylide used in the 
optimization of the reaction conditions was recovered unchanged when mixed with either 
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iodobenzene or bromobenzene and treated under the conditions that catalyze the cross-coupling of 
aryl iodides with α-diazo ketones,44 which could point to a less pronounced nucleophilic character 
of sulfoxonium ylides as compared to their diazo counterpart in these reactions. 
CONCLUSION 
In conclusion, we have reported a general palladium-catalyzed cross-coupling for the preparation 
of α-carbonyl-α’-(hetero)aryl sulfoxonium ylides from easily available (hetero)aryl bromides and 
triflates. The procedure shows excellent functional group tolerance and is amenable to the 
modification of active pharmaceutical ingredients and to the synthesis of an advanced precursor 
of drug candidates. We anticipate that the method of preparation of α-carbonyl-α’-(hetero)aryl 
sulfoxonium ylides reported herein will enable the development of numerous reactions based on 
these valuable and safe reagents. Finally, our findings suggest that the transmetallation of an 
(hetero)aryl-palladium(II) intermediate by sulfoxonium ylides and the subsequent deprotonation 
steps are rate-determining, in sharp contrast to comparable reactions of α-diazoketones. 
EXPERIMENTAL SECTION 
Otherwise noted, all reactions were carried out in flame-dried glassware under dry nitrogen 
atmosphere. All commercially available reagents were used as received. THF was used after 
passage through Innovative Technology PureSolv MD system. Acetonitrile was purchased as dry 
solvent. Pd2(dba)3 was purchased from Strem. XPhos was purchased from FluoroChem: the 
original container was stored in an argon-filled glovebox at room temperature and samples of 
approximately 1 g were taken out of the glove box as needed and stored in a Schlenck tube that 
was flushed with argon. Cesium carbonate (99.9%) was purchased from Sigma Aldrich. Flash 
chromatography: Merck silica gel 60 (230-400 mesh). NMR: the 1H, 13C{1H}, and 31P{1H} spectra 
were recorded on a Bruker DRX 500. The 19F{1H} spectra were recorded on a Bruker Avance 400 
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spectrometer. chemical shifts (δ) are given in ppm. The solvent signals were used as references for 
1H and 13C{1H} spectra (CDCl3: δ = 77.0; residual CHCl3 in CDCl3: δ = 7.26). The 
31P{1H} spectra 
were calibrated with an external standard (P(OPh)3, δ = 128.0 in CDCl3). The 
19F{1H} spectra were 
calibrated with an external standard ((trifluoromethyl)benzene, δ = -62.8). IR spectra were 
recorded on a PerkinElmer Spectrum 100 FT-IR spectrometer, and the wavenumbers (~ ) are given 
in cm-1. HRMS determined at the University of Liverpool on Agilent 6540A Accurate-Mass Q-
ToF MS with Agilent Jetstream Source (ES+). Melting points were measured on a Griffin melting 
point apparatus (not corrected). 
Mono-substituted α-carbonyl sulfoxonium ylides (1, 28, 32, 34, 38–47). Compounds 1,9 28,30 
34,9 38,8 39,8 40,55 41,39 42,9 43,8 44,33 45,1 and 4717 were prepared by the reported procedures. 
The 1H NMR chemical shifts of these compounds were in agreement with the literature values. 
Compounds 32 and 46 were prepared as described below. 
 
1-(3,5-Bis(trifluoromethyl)phenyl)-2-(dimethyl(oxo)-λ6-sulfaneylidene)ethan-1-one (32). 
Under nitrogen, trimethylsulfoxonium iodide (5.28 g, 24 mmol, 3.0 equiv) was suspended in dry 
THF (50 mL) in a flame-dried round bottom flask that was protected from light with aluminium 
foil. Potassium tert-butoxide (2.69 g, 24 mmol, 3.0 equiv) was added and the mixture was stirred 
at reflux for 2 hours. After cooling to 0 °C, from 3,5-bis(trifluoromethyl)benzoyl chloride (5.4 mL, 
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8.0 mmol, 1 equiv) in THF (16 mL) was added dropwise to the mixture via a dropping funnel. 
After stirring at room temperature for 1 hour, the mixture was filtered through a plug of celite 
(elution CH2Cl2). After evaporation of all volatiles, purification by flash chromatography (silica 
gel, petroleum ether/ethyl acetate = 3:7 to 1:9) and recrystallization from ethyl acetate/hexane gave 
compound 32 (7.86 g, 79%). White solid; m.p.: 152–154 °C. 1H NMR (500 MHz, CDCl3): δ 8.23 
(s, 2H), 7.93 (s, 1H), 5.06 (s, 1H), 3.85 (s, 6H). 13C{1H} NMR (125 MHz, CDCl3): δ 178.2, 140.9, 
131.6 (q, J = 33.3 Hz, 2C), 126.78, 126.75, 124.0 (hept, J = 3.7 Hz), 123.2 (q, J = 271.3 Hz, 2C), 
70.0, 42.2 (2C). 19F NMR (376 MHz, CDCl3): δ -62.9. IR (neat): ~  = 3103 (w), 3025 (w), 3005 
(w), 2921 (w), 1627 (w), 1548 (m), 1451 (w), 1406 (w), 1354 (m), 1311 (m), 1278 (s), 1191 (m), 
1166 (s), 1132 (s), 1106 (s0, 1027 (s), 996 (m), 956 (m), 924 (w), 909 (m), 900 (m), 859 (m), 844 
(m), 767 (w), 753 (w), 698 (w), 682 (w), 670 (w). HRMS (ESI): m/z calcd for C12H11F6O2S [M + 
H]+: 333.0378; found: 333.0382. 
2-(Dimethyl(oxo)-λ6-sulfaneylidene)-1-(5-methylisoxazol-3-yl)ethan-1-one (46). This 
compound (259 mg, 38%, white solid) was obtained from 5-methylisoxazole-3-carbonyl chloride 
(0.49 g, 3.4 mmol, 1 equiv) according to the method described for the preparation of 32 and after 
purification by flash chromatography (silica gel, CH2Cl2/MeOH = 98:2): 259 mg, 38%. White 
solid; m.p.: 117–119 °C. 1H NMR (500 MHz, CDCl3): δ 6.30 (q, J = 0.9 Hz, 1H), 5.33 (s, 1H), 
3.50 (s, 6H), 2.43 (d, J = 0.9 Hz, 3H). 13C{1H} NMR (125 MHz, CDCl3): δ 173.4, 170.0, 163.1, 
100.3, 70.7, 42.1, 12.3. IR (neat): ~  = 3140 (w), 3097 (w), 3009 (w), 2922 (w), 1599 (w), 1547 (s), 
1465 (w), 1449 (s), 1344 (s), 1318 (w), 1295 (w), 1245 (w), 1182 (s), 1133 (w), 1073 (w), 1020 
(s), 1008 (m), 996 (m), 979 (m), 941 (w), 901 (m), 848 (s), 827 (m), 813 (w), 768 (w), 753 (w), 
689 (w), 658 (w). HRMS (ESI): m/z calcd for C8H12NO3S [M + H]
+: 202.0532; found: 202.0530. 
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Representative procedure for the palladium-catalyzed cross-coupling of α-carbonyl 
sulfoxonium ylides. Under nitrogen, a J-Young Schlenck tube was charged with XPhos (38 mg, 
0.08 mmol, 0.2 equiv), Pd2dba3 (18 mg, 0.02 mmol, 0.05 equiv) and Cs2CO3 (143.4 mg, 0.44 
mmol, 1.1 equiv). Acetonitrile (0.4 mL) was then added and the mixture was stirred at room 
temperature for 10 minutes. Then, bromobenzene (160 μL, 2.5 mmol, 2.5 equiv) was added 
followed by sulfoxonium ylide 1 (87 mg, 0.4 mmol, 1 equiv). The inner wall of the Schlenck tube 
was rinsed with acetonitrile (0.4 mL) and the tube was then sealed, placed in a preheated oil bath 
set at 80 °C and stirred for 15 hours. The crude was then filtered over celite at room temperature 
using dichloromethane to transfer all the material and for rinsing. After evaporation of all volatiles 
under vacuum, purification by flash chromatography (silica gel; ethyl acetate/methanol: 9:1) 
afforded compound 2 (97 mg, 83%). 
3-Cyclohexyl-1-(dimethyl(oxo)-λ6-sulfaneylidene)-1-phenylpropan-2-one (2). Off-white solid; 
m.p.: 109-112 °C. 1H NMR (500 MHz, CDCl3): δ  7.36-7.27 (m, 3H), 7.25-7.21 (m, 2H), 3.47 (s, 
6H), 2.01 (d, J = 7.3 Hz, 2H), 1.84-1.71 (m, 1H), 1.67-1.52 (m, 5H), 1.27-1.14 (m, 2H), 1.11-0.97 
(m, 1H), 0.77 (q, J = 13.3 Hz, 2H). 13C{1H} NMR (125 MHz, CDCl3): δ 188.6, 134.8 (2C), 132.1, 
128.4, (2C), 127.7, 86.7, 45.4, 43.1 (2C), 35.2, 33.2 (2C), 26.3, 26.2 (2C). IR (neat): ~  = 3675 (w), 
3063 (w), 3014 (w), 2943 (w), 2916 (m), 2848 (w), 1534 (s), 1490 (w), 1439 (w), 1375 (s), 1312 
(w), 1294 (w), 1272 (w), 1225 (m), 1182 (s), 1112 (w), 1073 (w), 1007 (m), 994 (m), 965 (m), 939 
(m), 916 (w), 888 (w), 848 (w), 795 (w), 760 (w), 742 (m), 701 (s); HRMS (ESI): m/z calcd for 
C17H25O2S [M + H]
+: 293.1570; found: 293.1578. 
4-(1-(Dimethyl(oxo)-λ6-sulfaneylidene)-4-(1-methyl-1H-indol-3-yl)-2-oxobutyl)benzonitrile 
(3). Obtained from 38 (111 mg, 0.4 mmol, 1 equiv) and 4-bromobenzonitrile (182 mg, 1.0 mmol, 
2.5 equiv) following the representative procedure and after purification by flash chromatography 
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(silica gel; ethyl acetate/methanol = 9:1): 135 mg, 89%. Off-white solid; m.p.: 127–130 °C. 1H 
NMR (500 MHz, CDCl3): δ 7.43 (dt, J = 8.3, 2.1 Hz, 2H), 7.39 (d, J = 7.8 Hz, 1H), 7.25 (d, J = 
8.2 Hz, 1H), 7.19 (dd, J = 6.9, 0.8 Hz, 1H), 7.05-7.00 (m, 3H), 6.70 (s, 1H), 3.68 (s, 3H), 3.44 (s, 
6H), 3.02 (t, J = 7.4 Hz, 2H), 2.56 (t, J = 7.4 Hz, 2H). 13C{1H} NMR (125 MHz, CDCl3): δ 188.0, 
137.0, 136.6, 134.1 (2C), 131.4 (2C), 127.5, 126.0, 121.3, 118.7, 118.7, 188.3, 113.9, 109.9, 108.9, 
85.0, 43.1 (2C), 38.9, 32.3, 21.2. IR (neat): ~  = 3082 (w), 3038 (w), 3013 (w), 2967 (w), 2926 (w), 
2855 (w), 2226 (m), 1600 (w), 1560 (s), 1497 (w), 1485 (w), 1474 (w), 1450 (w), 1434 (w), 1419 
(w), 1395 (w), 1377 (w), 1343 (m), 1329 (m), 1321 (m), 1279 (w), 1264 (w), 1248 (w), 1223 (m), 
1205 (m), 1172 (s), 1119 (w), 1065 (m), 1036 (m), 1008 (w), 976 (w), 934 (m), 915 (w), 847 (w), 
800 (w), 748 (s), 735 (m), 697 (m), 656 (w). HRMS (ESI): m/z calcd for C22H23N2O2S [M + H]
+: 
379.1475; found: 379.1479. 
4-(1-(Dimethyl(oxo)-λ6-sulfaneylidene)-2-oxo-3-(1H-pyrrol-1-yl)propyl)benzonitrile (4). 
Obtained from 39 (80 mg, 0.4 mmol, 1 equiv) and 4-bromobenzonitrile (182 mg, 1.0 mmol, 2.5 
equiv) following the representative procedure and after purification by flash chromatography 
(silica gel; ethyl acetate/methanol = 97:3 to 93:7): 95 mg, 79%. Light-brown solid; m.p: 123–125 
°C. 1H NMR (500 MHz, CDCl3): δ 7.64 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 8.3 Hz, 2H), 6.52 (t, J = 
2.1 Hz, 2H), 6.11 (t, J = 2.1 Hz, 2H), 4.46 (s, 2H), 3.51 (s, 6H). 13C{1H} NMR (125 MHz, CDCl3): 
δ 180.9, 135.6, 134.4 (2C), 132.1 (2C), 121.4 (2C), 118.5, 111.2, 108.3 (2C), 83.9, 54.2, 42.9 (2C); 
IR (neat): ~  = 3094 (w), 3012 (w), 2915 (w), 2228 (m), 1603 (w), 1541 (s), 1500 (m), 1432 (w), 
1391 (w), 1382 (w), 1329 (w), 1296 (w), 1280 (w), 1226 (w), 1195 (s), 1183 (s), 1116 (w), 1095 
(w), 1070 (w), 1056 (w), 1013 (m), 986 (w), 969 (m), 955 (M), 932 (w), 908 (w), 888  (w), 847 
(w), 836 (w), 807 (w), 774 (w), 731 (s), 738 (s), 688 (w), 654 (w). HRMS (ESI): m/z calcd for 
C16H16N2NaO2S [M + Na]
+: 323.0825; found: 323.0823. 
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4-(3-(Benzyloxy)-1-(dimethyl(oxo)-λ6-sulfaneylidene)-2-oxopropyl)benzonitrile (5). Obtained 
from 40 (96 mg, 0.4 mmol, 1 equiv) and 4-bromobenzonitrile (182 mg, 1.0 mmol, 2.5 equiv) 
following the representative procedure and after purification by flash chromatography (silica gel; 
ethyl acetate/methanol = 9:1): 112 mg, 82%. Orange oil. 1H NMR (500 MHz, CDCl3): δ 7.56 (dt, 
J = 8.4, 1.9 Hz, 2H), 7.35-7.21 (m, 7H), 4.52 (s, 2H), 4.00 (s, 2H), 3.57 (s, 6H). 13C{1H} NMR 
(125 MHz, CDCl3): δ 183.2, 137.4, 135.8, 133.8 (o, 2C), 131.6 (o, 2C), 128.1 (o, 2C), 127.7 (o, 
2C), 127.5 (o), 118.6 (e), 110.4 (e), 84.1 (e), 73.1 (e), 71.8 (e), 42.9 (o, 2C). IR (neat): ~   = 3006 
(w), 2919 (w), 2858 (w), 2224 (m), 1542 (s), 1499 (m), 1454 (w), 1404 (m), 1328 (m), 1307 (m), 
1198 (s), 1179 (s), 1104 (s), 1020 (s), 970 (m), 942 (w), 912 (w), 837 (w), 734 (s), 699 (m), 683 
(w). HRMS (ESI): m/z calcd for C19H20NO3S [M + H]
+: 342.1158; found: 342.1165. 
Tert-butyl (4-(4-cyanophenyl)-4-(dimethyl(oxo)-λ6-sulfaneylidene)-3-oxobutan-2-
yl)carbamate (6). Obtained from racemic 41 (105 mg, 0.4 mmol, 1 equiv) and 4-
bromobenzonitrile (182 mg, 1.0 mmol, 2.5 equiv) following the representative procedure and after 
purification by flash chromatography (silica gel; ethyl acetate/methanol = 95:5 to 92:8): 127 mg, 
87%. Yellow solid; m.p.: 130-133 °C. 1H NMR (500 MHz, CDCl3): δ 7.57 (d, J = 8.2 Hz, 2H), 
7.39 (d, J = 7.9 Hz, 2H), 5.28 (d, J = 7.3 Hz, 1H), 4.29 (q, J = 7.3 Hz, 1H), 3.53 (s, 3H), 3.42 (s, 
3H), 1.35 (s, 9H), 1.00 (d, J = 6.9 Hz, 3H); 13C{1H} NMR (125 MHz, CDCl3): δ 186.5 (e), 154.8 
(e), 135.9 (e), 134.6 (o, 2C), 132.0 (o, 2C), 118.6 (e), 110.9 (e), 83.1 (e), 78.9 (e), 49.5 (o), 42.9 
(o), 42.8 (o), 28.2 (o, 3C), 19.3 (o); IR (neat): ~  = 3245 (m, br), 2934 (m), 2934 (w), 2227 (m), 
1685 (s), 1603 (w), 1536 (s), 1452 (w), 1391 (m), 1365 (m), 1337 (w), 1311 (w), 1296 (m), 1280 
(m), 1253 (m), 1213 (m), 1199 (s), 1165 (s), 1107 (m), 1058 (m), 1011 (s), 963 (m), 943 (m), 880 
(w), 852 (w), 792 (w), 744 (m), 681 (m).  HRMS (ESI): m/z calcd for C18H25N2O4S [M + H]
+: 
365.1530; found: 365.1532. 
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Tert-butyl 4-(2-(4-cyanophenyl)-2-(dimethyl(oxo)-λ6-sulfaneylidene)acetyl)piperidine-1-
carboxylate (7). Obtained from 42 (121 mg, 0.4 mmol, 1 equiv) and 4-bromobenzonitrile (182 
mg, 1.0 mmol, 2.5 equiv) following the representative procedure (after purification by flash 
chromatography (ethyl acetate/methanol = 95:5 to 92:8): 138 mg, 85%. Off-white solid; m.p.: 154–
156 °C. 1H NMR (500 MHz, CDCl3): δ 7.59 (d, J = 8.5 Hz, 2H), 7.30 (d, J = 8.3 Hz, 2H), 4.01 (br 
s, 2H), 3.49 (s, 6H), 2.57-2.36 (m, 3H), 1.60 (qd, J = 12.8, 4.4 Hz, 2H), 1.53-1.42 (m, 2H), 1.38 
(s, 9H). 13C{1H} NMR (125 MHz, CDCl3): δ 189.9, 154.5, 136.8, 134.3 (2C), 131.9 (2C), 118.6, 
110.7, 84.1, 79.2, 43.4 (2C), 43.1 (2C, not visible but inferred from HSQC), 42.8, 28.4 (2C), 28.3 
(3C); IR (neat): ~  = 3667 (w), 3008 (w), 2976 (w), 2919 (w), 2855 (w), 2228 (m), 1673 (s), 1601 
(w), 1571 (w), 1540 (s), 1499 (w), 1477 (w), 1466 (w), 1431 (m), 1388 (m), 1364 (w), 1349 (w), 
1304 (w), 1273 (w), 1242 (w), 1192 (s), 1159 (s), 1125 (m), 1068 (w), 1031 (s), 989 (w), 965 (m), 
945 (w), 928 (w), 865 (w), 845 (w), 812 (w), 756 (w), 727 (s), 680 (w). HRMS (ESI): m/z calcd 
for C21H29N2O4S [M + H]
+: 405.1843; found: 405.1849. 
4-(1-(Dimethyl(oxo)-λ6-sulfaneylidene)-2-oxo-3,3-diphenylpropyl)benzonitrile (8). Obtained 
from 43 (115 mg, 0.4 mmol, 1 equiv) and 4-bromobenzonitrile (182 mg, 1.0 mmol, 2.5 equiv) 
following the representative procedure and after purification by flash chromatography (silica gel; 
petroleum ether/ethyl acetate = 1:4): 138 mg, 89%. Pale-orange solid; m.p.: 99–102 °C. 1H NMR 
(500 MHz, CDCl3): δ 7.56 (d, J = 7.6 Hz, 2H), 7.30-7.16 (m, 12H), 5.01 (s, 1H), 3.49 (s, 6H). 
13C{1H} NMR (125 MHz, CDCl3): δ 185.9, 140.5 (2C), 136.7, 134.7 (2C), 131.7 (2C), 128.6 (4C), 
128.2 (4C), 126.4 (2C), 118.6, 110.8, 85.5, 57.7, 43.0 (2C). IR (neat): ~  = 3674 (w), 3083 (w), 
3060 (w), 3029 (w), 3008 (w), 2913 (w), 2221 (m), 1755 (w), 1718 (w), 1673 (w), 1600 (m), 1539 
(s), 1495 (m), 1448 (w), 1397 (w), 1371 (m), 1302 (m), 1272 (w), 1198 (s), 1180 (m), 1110 (w), 
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1077 (w), 10323 (w), 1014 (m), 970 (m), 957 (w), 935 (m), 877 (w), 836 (m), 782 (w), 734 (s), 
704 (s), 681 (m). HRMS (ESI): m/z calcd for C24H22NO2S [M + H]
+: 388.1366; found: 388.1363. 
4-(2-(3,5-Bis(trifluoromethyl)phenyl)-1-(dimethyl(oxo)-λ6-sulfaneylidene)-2-
oxoethyl)benzonitrile (9). Obtained from 32 (132 mg, 0.4 mmol, 1 equiv) and 4-
bromobenzonitrile (182 mg, 1.0 mmol, 2.5 equiv) following the representative procedure and after 
purification by flash chromatography (silica gel; petroleum ether/ethyl acetate = 6:4 to 3:7): 142 
mg, 82%. Yellow solid; m.p.: 91–94 °C; 1H NMR (500 MHz, CDCl3): δ 7.73 (s, 3H), 7.47 (d, J = 
8.1 Hz, 2H), 7.18 (d, J = 8.1 Hz, 2H), 3.67 (s, 6H). 13C NMR (125 MHz, CDCl3): δ 179.1, 141.4, 
136.4, 134.3 (2C), 131.8 (2C), 131.0 (q, J = 34.0 Hz, 2C), 128.9* (q, J = 2.6 Hz), 123.1 (sept, J = 
3.7 Hz, 2C), 121.7 (q, J = 273.2 Hz, 2C), 118.5, 110.6, 86.8, 42.8 (2C) (the signal marked by an 
asterisk is an unresolved quartet; the coupling constant was determined from the two central 
resonances). 19F{1H} NMR (376 MHz, CDCl3): δ -63.2. IR (neat): ~  = 3675 (w), 3075 (w), 3004 
(w), 2989 (w), 2918 (w), 2223 (m), 1624 (w), 1602 (w), 1538 (s), 1505 (m), 1444 (w), 1407 (w), 
1389 (w), 1349 (m), 1275 (s), 1240 (m), 1211 (m), 1196 (m), 1169 (s), 1112 (s), 1027 (s), 991 (w), 
968 (w), 944 (w), 922 (w), 891 (s), 844 (m), 835 (m), 754 (m), 729 (m), 698 (m), 678 (s). HRMS 
(ESI): m/z calcd for C19H14F6NO2S [M + H]
+: 434.0644; found: 434.0644. 
4-(1-(Dimethyl(oxo)-λ6-sulfaneylidene)-2-(4-methoxyphenyl)-2-oxoethyl)benzonitrile (10). 
Obtained from 44 (91 mg, 0.4 mmol, 1 equiv) and 4-bromobenzonitrile (182 mg, 1.0 mmol, 2.5 
equiv) following the representative procedure and after purification by flash chromatography 
(silica gel; ethyl acetate/methanol = 95:5 to 90:10): 105 mg, 80%. Yellow solid; m.p.: 149–152 
°C. 1H NMR (500 MHz, CDCl3): δ 7.40 (d, J = 8.5 Hz, 2H), 7.24 (d, J = 8.7 Hz, 2H), 7.18 (d, J = 
8.5 Hz, 2H), 6.65 (d, J = 8.8 Hz, 2H), 3.71 (s, 3H), 3.60 (s, 6H). 13C{1H} NMR (125 MHz, CDCl3): 
δ 183.1, 160.8, 138.0, 133.9 (2C), 131.8, 131.3 (2C), 130.4 (2C), 119.0, 112.8 (2C), 109.2, 84.5, 
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55.0, 43.3 (2C). IR (neat): ~  = 2991 (w), 2914 (w), 2839 (w), 2228 (s), 1601 (m), 1579 (m), 1505 
(s), 1494 (s), 1463 (w), 1374 (s), 1303 (m), 1250 (s), 1187 (s), 1171 (s), 1119 (w), 1016 (s), 984 
(w), 967 (w), 954 (m), 942 (m), 861 (w), 844 (s), 818 (m), 781 (w), 770 (w), 757 (s), 728 (m), 689 
(w), 675 (w). HRMS (ESI): m/z calcd for C18H18NO3S [M + H]
+: 328.1002; found: 328.1007. 
4-(1-(Dimethyl(oxo)-λ6-sulfaneylidene)-2-oxo-2-(thiophen-2-yl)ethyl)benzonitrile (11). 
Obtained from 45 (81 mg, 0.4 mmol, 1 equiv) and 4-bromobenzonitrile (182 mg, 1.0 mmol, 2.5 
equiv) following the representative procedure and after purification by flash chromatography 
(silica gel, ethyl acetate to ethyl acetate/methanol = 95:5): 95 mg, 82%. Off-white solid; m.p.: 201–
203 °C. 1H NMR (500 MHz, CDCl3): δ 7.62-7.57 (m, 2H), 7.44-7.40 (m ,2H), 7.32 (dd, J = 5.0, 
1.1 Hz, 1H), 6.81 (dd, J = 5.0, 3.8 Hz, 1H), 6.66 (dd, J = 3.8, 1.0 Hz, 1H), 3.65 (s, 6H). 13C{1H} 
NMR (125 MHz, CDCl3): δ 174.4, 144.8, 136.7, 135.5 (2C), 132.0 (2C), 129.6, 129.3, 127.1, 
118.8, 111.3, 83.9, 43.6 (2C). IR (neat): ~   = 3112 (w), 3069 (w), 3023 (w), 2999 (m), 2914 (w), 
2220 (m), 1601 (w), 1518 (m), 1504 (s), 1492 (s), 1415 (m), 1405 (m), 1380 (s), 1347 (w), 1306 
(w), 1289 (w), 1251 (m), 1230 (w), 1191 (s), 1180 (s), 1108 (w), 1092 (m), 1071 (w), 1044 (w), 
1020 (s), 980 (m), 962 (m), 947 (s), 868 (w), 846 (m), 831 (w), 763 (m), 741 (m), 718 (s), 674 (m), 
664 (m). HRMS (ESI): m/z calcd for C15H14NO2S2 [M + H]
+: 304.0460; found: 304.0495. 
4-(1-(Dimethyl(oxo)-λ6-sulfaneylidene)-2-(5-methylisoxazol-3-yl)-2-oxoethyl)benzonitrile 
(12). Obtained from 46 (80 mg, 0.4 mmol, 1 equiv) and 4-bromobenzonitrile (182 mg, 1.0 mmol, 
2.5 equiv) following the representative procedure and after purification by flash chromatography 
(silica gel, ethyl acetate/methanol = 95:5 to 92:8): 100 mg, 83%. Beige solid; m.p.: 162–165 °C. 
1H NMR (500 MHz, CDCl3): δ 7.53 (dt, J = 8.5, 1.8 Hz, 2H), 7.32 (dt, J = 8.5, 1.8 Hz, 2H), 5.90 
(s, 1H), 3.66 (s, 6H), 2.33 (s, 3H). 13C{1H} NMR (125 MHz, CDCl3): δ 172.2, 169.0, 162.3, 135.6, 
134.4 (2C), 131.4 (2C), 118.7, 110.6, 101.1, 88.1, 42.5 (2C), 11.9. IR (neat): ~  = 3122 (w), 2995 
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(w), 2914 (w), 2227 (m), 1601 (m), 1526 (s), 1444 (m), 1406 (m), 1348 (m), 1308 (m), 1274 (w), 
1260 (m), 1992 (s), 1108 (w), 1017 (s), 986 (w), 961 (m), 943 (s), 920 (w), 900 (m), 846 (m), 792 
(w), 765 (m), 738 (w), 727 (w), 681 (m), 657 (w). HRMS (ESI): m/z calcd for C15H14N2NaO3S [M 
+ Na]+: 325.0617; found: 325.0622. 
1-(Dimethyl(oxo)-λ6-sulfaneylidene)-1-phenylpropan-2-one (13). Obtained from 34 (134 mg, 
1.0 mmol, 1 equiv) and bromobenzene (160 μL, 2.5 mmol, 2.5 equiv) following the representative 
procedure and after purification by flash chromatography on a short pad of silica gel (ethyl 
acetate/methanol = 90:10 to 87:13): 147 mg, 70%. Amorphous solid. 1H NMR (500 MHz, CDCl3): 
δ 7.42-7.25 (m, 5H), 3.49 (s, 6H), 1.90 (s, 3H). 13C{1H} NMR (125 MHz, CDCl3): δ 186.4, 134.3 
(2C), 132.5, 128.4 (2C), 127.7, 85.8, 42.9 (2C), 26.5. IR (neat): ~  = 3393 (w), 3013 (m), 2921 (m), 
1532 (s), 1489 (m), 1410 (w), 1366 (s), 1308 (w), 1234 (s), 1166 (s), 1023 (s), 1001 (s), 967 (m), 
939 (w), 914 (w), 850 (w), 804 (w), 760 (m), 738 (w), 702 (s), 661 (w), 654 (w). HRMS (ESI): 
m/z calcd for C11H15O2S [M + H]
+: 211.0787; found: 211.0790. 
1-(Dimethyl(oxo)-λ6-sulfaneylidene)-1-(p-tolyl)propan-2-one (14). Obtained from 34 (54 mg, 
0.4 mmol, 1 equiv) and 4-bromotoluene (123 μL, 1.0 mmol, 2.5 equiv) following the representative 
procedure and after purification by flash chromatography on a short pad of silica gel (ethyl 
acetate/methanol = 90:10 to 86:14): 62 mg, 69%. Amorphous solid. 1H NMR (500 MHz, CDCl3): 
δ 7.14 (apparent broad s, 4H), 3.46 (s, 6H), 2.35 (s, 3H), 1.88 (s, 3H). 13C{1H} NMR (125 MHz, 
CDCl3): δ 186.5, 137.6, 134.2 (2C), 129.4, 129.3 (2C), 85.4, 42.8 (2C), 26.5, 21.1; IR (neat): ~  = 
3350 (m), 3018 (m), 2920 (m), 2232 (w), 1536 (s), 1509 (m), 1406 (m), 1366 (s), 1306 (w), 1234 
(s), 1165 (s), 1107 (w), 1024 (s), 970 (m), 940 (w), 923 (w), 814 (m), 794 (w), 722 (s), 695 (m). 
HRMS (ESI): m/z calcd for C12H17O2S [M + H]
+: 225.0944; found: 225.0947. 
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1-(Dimethyl(oxo)-λ6-sulfaneylidene)-1-(4-methoxyphenyl)propan-2-one (15). This compound 
was obtained from 34 (54 mg, 0.4 mmol, 1 equiv) and 4-bromo-anisole (125 μL, 1.0 mmol, 2.5 
equiv) following the representative procedure.  The compound underwent degradation under the 
reaction conditions but the maximal yield reached 51% after 2 hours of reaction as judged by 1H 
NMR with internal standard (1,3,5-trimethoxybenzene). Attempted purification by flash 
chromatography on a short pad of silica gel (ethyl acetate/methanol = 4:1 to 1:1) gave 26% of the 
compound contaminated by some remaining starting material 34 (5%) and DMSO (1%). Only the 
resonances corresponding to 15 are described herein. 1H NMR (500 MHz, CDCl3): δ 7.17 (dt, J = 
8.7, 2.1 Hz 2H), 6.88 (dt, J = 8.7, 2.1 Hz, 2H), 3.81 (s, 3H), 3.46 (s, 6H), 1.87 (s, 3H); 13C NMR 
(125 MHz, CDCl3): δ 186.8, 159.3, 135.7 (2C), 124.5, 113.4 (2C), 85.0, 55.2, 42.8 (2C), 26.5. 
1-(Dimethyl(oxo)-λ6-sulfaneylidene)-1-(4-nitrophenyl)propan-2-one (16). Obtained from 34 
(54 mg, 0.4 mmol, 1 equiv) and 1-bromo-4-nitrobenzene (202 mg, 1.0 mmol, 2.5 equiv) following 
the representative procedure and after purification by flash chromatography (silica gel, ethyl 
acetate/methanol = 95:5 to 90:10): 92 mg, 90%. Yellow solid; m.p.: 135-140 °C. 1H NMR (500 
MHz, CDCl3): δ 8.13 (dt, J = 8.9, 2.1 Hz, 2H), 7.36 (dt, J = 8.9, 2.1 Hz, 2H), 3.56 (s, 6H), 1.98 (s, 
3H); 13C{1H} NMR (125 MHz, CDCl3): δ 186.0, 146.0, 139.8, 133.5 (2C), 123.1 (2C), 84.6 (e), 
43.5 (2C), 26.5. IR (neat): ~  = 3066 (w), 3022 (w), 3000 (w), 2916 (m), 2436 (w), 1586 (m), 1526 
(s), 1508 (s), 1437 (w), 1405 (w), 1363 (m), 1346 (m), 1324 (s), 1307 (m), 1245 (m), 1194 (s), 
1108 (s). HRMS (ESI): m/z calcd for C11H14NO4S [M + H]
+: 256.0638; found: 256.0644. 
4-(1-(Dimethyl(oxo)-λ6-sulfaneylidene)-2-oxopropyl)benzonitrile (17). Obtained from 34 (54 
mg, 0.4 mmol, 1 equiv) and 4-bromobenzonitrile (182 mg, 1.0 mmol, 2.5 equiv) following the 
representative procedure and after purification by flash chromatography (silica gel, ethyl 
acetate/methanol = 95:5 to 85:15): 70 mg, 74%. Yellow solid; m.p.: 106-109 °C. 1H NMR (500 
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MHz, CDCl3): δ 7.55 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.5 Hz, 2H), 3.51 (s, 6H), 1.92 (s, 3H). 
13C{1H} NMR (125 MHz, CDCl3): δ 185.8, 137.6, 133.8 (2C), 131.7 (2C), 118.8, 110.0, 84.7, 43.3 
(2C), 26.4. IR (neat): ~  = 3411 (w), 3054 (w), 3016 (m), 2995 (m), 2910 (m), 2227 (s), 1601 (m), 
1521 (s), 1403 (w), 1376 (s), 1348 (w), 1310 (m), 1267 (w), 1242 (m), 1200 (s), 1114 (w), 1033 
(s), 1011 (m), 985 (w), 968 (s), 949 (s), 917 (w), 865 (w), 850 (m), 840 (m), 777 (m), 732 (s), 685 
(s). HRMS (ESI): m/z calcd for C12H14NO2S [M + H]
+: 236.0740; found: 236.0742. 
1-(Dimethyl(oxo)-λ6-sulfaneylidene)-1-(4-(trifluoromethyl)phenyl)propan-2-one (18). 
Obtained from 34 (54 mg, 0.4 mmol, 1 equiv) and 4-bromobenzotrifluoride (140 μL, 1.0 mmol, 
2.5 equiv) following the representative procedure) and after purification by flash chromatography 
(silica gel, ethyl acetate/methanol = 9:1): 96 mg, 86. Off-white amorphous solid. 1H NMR (500 
MHz, CDCl3): δ 7.54 (d, J = 8.2 Hz, 2H), 7.33 (d, J = 8.1 Hz, 2H), 3.48 (s, 6H), 1.89 (s, 3H). 
13C{1H} NMR (125 MHz, CDCl3): δ 186.0, 136.3, 134.0 (2C), 128.9 (q, J = 32.0 Hz), 125.0 (q, J 
= 3.5 Hz, 2C) 124.1 (q, J = 272.0 Hz), 84.5, 43.1 (2C), 26.4 (o). 19F{1H} NMR (376 MHz, CDCl3): 
δ -62.4. IR (neat): ~  = 3025 (w), 2925 (w), 1609 (w), 1538 (s), 1403 (w), 1376 (m), 1322 (s), 1241 
(m), 1177 (s), 1110 (s), 1067 (s), 1019 (m), 1005 (m), 983 (w), 972 (w), 946 (w), 835 (s), 777 (w), 
735 (m), 701 (m), 664 (w). HRMS (ESI): m/z calcd for C12H14F3O2S [M + H]
+: 279.0661; found: 
279.0667. 
1-(4-Chlorophenyl)-1-(dimethyl(oxo)-λ6-sulfaneylidene)propan-2-one (19). Obtained from 34 
(54 mg, 0.4 mmol, 1 equiv) and 1-bromo-4-chlorobenzene (192 mg, 1.0 mmol, 2.5 equiv) 
following the representative procedure and after purification by flash chromatography (silica gel, 
ethyl acetate/methanol = 95:5 to 85:15): 68 mg, 69%. Yellow solid; m.p.: 111–114 °C. 1H NMR 
(500 MHz, CDCl3): δ 7.28 (dt, J = 8.5, 2.5 Hz, 2H), 7.16 (dt, J = 8.6, 2.1 Hz, 2H), 3.46 (s, 6H), 
1.86 (s, 3H). 13C{1H} NMR (125 MHz, CDCl3): δ 186.1, 135.4 (2C), 133.6, 130.8, 128.5 (2C), 
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84.2, 42.9 (2C), 26.4. IR (neat): ~  = 3050 (w), 3030 (w), 3014 (m), 2998 (w), 2929 (m), 1587 (w), 
1552 (s), 1488 (m), 1421 (w), 1395 (w), 1361 (s), 1343 (m), 1322 (w), 1259 (w), 1235 (s), 1177 
(w), 1156 (s), 1101 (w), 1086 (m), 1057 (w), 1033 (s), 1012 (s), 989 (m), 979 (s), 924 (m), 911 
(m), 842 (m), 818 (m), 752 (m), 730 (w), 718 (m), 689 (m). HRMS (ESI): m/z calcd for 
C11H14ClO2S [M + H]
+: 245.0398; found: 245.0402. 
1-(3,5-Difluorophenyl)-1-(dimethyl(oxo)-λ6-sulfaneylidene)propan-2-one (20). Obtained from 
34 (54 mg, 0.4 mmol, 1 equiv) and 1-bromo-3,5-difluorobenzene (110 µL, 1.0 mmol, 2.5 equiv) 
following the representative procedure and after purification by flash chromatography (silica gel, 
ethyl acetate/methanol = 95:5 to 90:10): 68 mg, 69%. Yellow solid; m.p.: 134–136 °C. 1H NMR 
(500 MHz, CDCl3): δ 6.82–6.70 (m, 3H), 3.51 (s, 6H), 1.93 (s, 3H). 
13C{1H} NMR (125 MHz, 
CDCl3): δ 186.1, 163.4 (d, J = 13.6 Hz, 2C), 161.5 (d, J = 13.6 Hz), 135.6 (t, J = 10.0 Hz), 116.7 
(dd, J = 19.0, 5.8 Hz, 2C), 103.0 (t, J = 25.4 Hz), 43.2 (2C), 26.5 (o); 19F{1H} NMR (125 MHz, 
CDCl3): δ -110.6. IR (neat): ~  = 3675 (w), 3063 (w), 3014 (w), 2943 (w), 2916 (m), 2848 (w), 
1534 (s), 1490 (w), 1439 (w), 1375 (s), 1312 (w), 1294 (w), 1272 (w), 1225 (m), 1182 (s), 1112 
(w), 1073 (w), 1007 (m), 994 (m), 965 (m), 939 (m), 916 (w), 888 (w), 848 (w), 795 (w), 760 (w), 
742 (m), 701 (s). HRMS (ESI): m/z calcd for C11H13F2O2S [M + H]
+: 247.0608; found: 247.0599. 
1-(Dimethyl(oxo)-λ6-sulfaneylidene)-3,3-diphenyl-1-(thiophen-3-yl)propan-2-one (21). 
Obtained from 43 (115 mg, 0.4 mmol, 1 equiv) and 3-bromothiophene (94 μL, 1.0 mmol, 2.5 
equiv) following the representative procedure and after purification by flash chromatography 
(silica gel, hexane/ethyl acetate = 1:1 to 1:4): 92 mg, 63%. Off-white solid; m.p.: 118–120 °C. 1H 
NMR (500 MHz, CDCl3): δ 7.32–7.16 (m, 11H), 7.03 (dd, J = 2.9, 1.0 Hz, 1H), 6.83 (dd, J = 4.8, 
0.9 Hz, 1H), 5.03 (s, 1H), 3.40 (s, 6H). 13C{1H} NMR (125 MHz, CDCl3): δ 187.0, 141.3 (2C), 
132.5, 131.0, 129.3, 129.0 (4C), 128.3 (4C), 126.4 (2C), 125.2, 80.6, 57.9, 42.5 (2C). IR (neat): ~  
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=  3081 (w), 3060 (w), 3026 (w), 2929 (w), 1753 (w), 1716 (w), 1656 (w), 1560 (s), 1492 (m), 
1447 (w), 1392 (w), 1344 (m), 1315 (w), 1304 (w), 1248 (w), 1210 (w), 1168 (s) 1155 (s), 1076 
(w), 1028 (s), 953 (w), 927 (w), 904 (w), 876 (w), 850 (m), 807 (m), 783 (w), 752 (w), 736 (m), 
714 (s), 699 (s), 683 (s). HRMS (ESI): m/z calcd for C21H21O2S2 [M + H]
+: 369.0977; found: 
369.0978. 
1-(Dimethyl(oxo)-λ6-sulfaneylidene)-1-(2,6-dimethylpyridin-4-yl)propan-2-one (22). 
Obtained from 34 (54 mg, 0.4 mmol, 1 equiv) and 4-bromo-2,6-dimethylpyridine (186 mg, 1 
mmol, 2.5 equiv) following the representative procedure and after purification by flash 
chromatography (silica gel, ethyl acetate/methanol = 85:15 to 80:20): 92 mg, 96%. Yellow solid; 
m.p.: 138–141 °C. 1H NMR (500 MHz, CDCl3): δ 6.74 (s, 2H), 3.44 (s, 6H), 2.41 (s, 6H), 1.88 (s, 
3H); 13C{1H} NMR (125 MHz, CDCl3): δ 185.9, 157.2 (2C), 141.2, 124.2 (2C), 84.1, 43.2 (2C), 
26.3, 24.2 (2C); IR (neat): ~  = 3037 (w), 2977 (w), 2922 (w), 2904 (w), 1597 (m), 1567 (s), 1549 
(s), 1397 (m), 1384 (m), 1356 (m), 1291 (s), 1221 (w), 1170 (s), 1063 (m), 1031 (s), 998 (m), 948 
(w), 911 (w), 893 (w), 870 (w), 787 (w), 756 (w), 741 (m), 688 (m). HRMS (ESI): m/z calcd for 
C12H18NO2S [M + H]
+: 240.1053; found: 240.1057. 
1-([1,1'-Biphenyl]-4-yl)-3-cyclohexyl-1-(dimethyl(oxo)-λ6-sulfaneylidene)propan-2-one (23). 
Obtained from 1 (87 mg, 0.4 mmol, 1 equiv) and (1,1'-biphenyl)-4-yl trifluoromethanesulfonate57 
(302 mg, 1.0 mmol, 2.5 equiv) following the representative procedure and after purification by 
flash chromatography (silica gel, ethyl acetate/methanol = 95:5 to 92/8): 79 mg, 54%. White solid; 
m.p.: 126–128 °C. 1H NMR (500 MHz, CDCl3): δ 7.62 (d, J = 7.3 Hz, 2H), 7.57 (d, J = 8.1 Hz, 
2H), 7.43 (t, J = 7.7 Hz, 2H), 7.33 (t, J = 7.4 Hz,  1H), 7.29 (d, J = 8.3 Hz, 2H), 3.49 (s, 6H), 2.08 
(d, J = 7.1 Hz, 2H), 1.87-1.76 (m, 1H), 1.76-1.70 (m, 5H), 1.29-1.18 (m, 2H), 1.12-1.00 (m, 1H), 
0.86-0.76 (m, 2H). 13C{1H} NMR (125 MHz, CDCl3): δ 188.5, 140.4, 140.2, 135.0 (2C), 131.0, 
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128.7 (2C), 127.3, 127.0 (2C), 126.9 (2C), 86.2, 45.4, 43.1 (2C), 35.2, 33.1 (2C), 26.3, 26.2 (2C). 
IR (neat): ~  = 3025 (w), 2918 (s), 2846 (m), 1550 (s), 1485 (m), 1446 (w), 1374 (m), 1321 (w), 
1276 (w), 1254 (w), 1228 (m), 1177 (s), 1164 (s), 1112 (m), 1076 (w), 1066 (w), 1008 (m), 1019 
(m), 969 (w), 937 (w), 889 (w), 836 (w), 796 (w), 765 (m), 730 (s), 693 (s). HRMS (ESI): m/z 
calcd for C23H29O2S [M + H]
+: 369.1883; found: 369.1887. 
7-(1-(Dimethyl(oxo)-λ6-sulfaneylidene)-2-oxo-3,3-diphenylpropyl)-2H-chromen-2-one (24). 
Obtained from 43 (115 mg, 0.4 mmol, 1 equiv) and 2-oxo-2H-chromen-7-yl 
trifluoromethanesulfonate7 (294 mg, 1.0 mmol, 2.5 equiv) following the representative procedure 
but using 2 mL of acetonitrile and after purification by flash chromatography (silica gel, petroleum 
ether/ethyl acetate = 1:1 to ethyl acetate only) and trituration with diethyl ether: 86 mg, 50%. 
Coral-colored solid; m.p.: 134–138 °C. 1H NMR (500 MHz, CDCl3): δ 7.68 (d, J = 9.5 Hz, 1H), 
7.38 (d, J = 7.9 Hz, 1H), 7.29-7.23 (m, 4H), 7.23-7.17 (m, 6H), 7.14 (d, J = 0.8 Hz, 1H), 7.04 (dd, 
J = 7.9, 1.5 Hz, 1H), 6.41 (d, J = 9.5 Hz, 1H), 5.07 (s, 1H), 3.53 (s, 6H). 13C{1H} NMR (125 MHz, 
CDCl3): δ 186.1, 160.5, 153.6, 142.9, 140.7 (2C), 135.7, 130.6, 128.8 (4C), 128.3 (4C), 127.2, 
126.5 (2C), 122.1, 118.0, 116.6, 85.5, 57.7, 43.1 (2C). IR (neat): ~  = 3660 (w), 3060 (w), 3025 
(w), 3008 (m), 2924 (w), 1721 (s), 1610 (m), 1540 (s), 1493 (m), 1449 (w), 1402 (m), 1360 (m), 
1308 (m), 1290 (w), 1278 (w), 1247 (m), 1227 (w), 1193 (s), 1152 (m), 1134 (m), 1103 (m), 1077 
(w), 1024 (s), 1013 (m), 982 (m), 941 (m), 924 (m), 909 (w), 897 (w), 878 (w), 816 (w), 784 (w), 
770 (w), 750 (m), 727 (m), 719 (s), 695 (s). HRMS (ESI) m/z calcd for C26H22NaO4S [M + Na]
+: 
453.1131; found: 453.1136. 
4-(1-(Dimethyl(oxo)-λ6-sulfaneylidene)-2-oxoethyl)benzonitrile (25). Obtained from 47 (48 
mg, 0.4 mmol, 1 equiv) and 4-bromobenzonitrile (182 mg, 1 mmol, 2.5 equiv) following the 
representative procedure and after purification by flash chromatography on a short pad of silica 
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gel (ethyl acetate/methanol = 92:8 to 85:15; the silica was pre-treated with an ethyl 
acetate/methanol/triethylamine (92:8:1) mixture, and then washed with ethyl acetate/methanol 
(92:8) before loading the crude mixture): 74 mg, 83%. Beige amorphous solid. 1H NMR (500 
MHz, CDCl3): δ 8.92 (s, 1H), 7.54 (d, J = 8.5 Hz, 2H), 7.35 (d, J = 8.6 Hz, 2H), 3.58 (s, 6H). 
13C{1H} NMR (125 MHz, CDCl3): δ 178.0, 137.2, 132.0 (2C), 128.5 (2C), 119.1, 108.5, 87.5, 42.6 
(2C). IR (neat): ~  = 3661 (w), 3028 (w), 2989 (w), 2919 (w), 2903 (w), 2219 (m), 1577 (s), 1503 
(m), 1415 (w), 1391 (m), 1313 (s), 1303 (s), 1275 (w), 1189 (s), 1175 (s), 1113 (w), 1076 (w), 1066 
(w), 1056 (w), 1025 (s), 984 (m), 959 (m), 946 (m), 919 (w), 835 (m), 819 (m), 770 (w), 739 (m), 
724 (w), 703 (m), 656 (w). HRMS (ESI): m/z calcd for C11H12NO2S [M + H]
+: 222.0583; found: 
222.0585. 
2-(1-(Dimethyl(oxo)-λ6-sulfaneylidene)-2-oxoethyl)benzonitrile (26). Obtained from 47 (54 
mg, 0.4 mmol, 1 equiv) and 2-bromobenzonitrile (182 mg, 1 mmol, 2.5 equiv) following the 
representative procedure and after purification by flash chromatography on a short pad of silica 
gel (ethyl acetate/methanol = 90:10 to 84:16; the silica was pre-treated with an ethyl 
acetate/methanol/triethylamine (90:10:1) mixture, and then washed with ethyl acetate/methanol 
(90:10) before loading the crude mixture): 76 mg, 85%. Beige amorphous solid. 1H NMR (500 
MHz, CDCl3): δ 8.75 (s, 1H), 7.63 (dd, J = 7.8, 1.1 Hz, 1H), 7.52 (td, J = 7.8, 1.5 Hz, 1H), 7.38-
7.31 (m, 2H), 3.61 (s, 6H). 13C{1H} NMR (125 MHz, CDCl3): δ 177.5, 134.9, 134.1, 132.8, 132.6, 
127.5, 119.5, 116.1, 84.9, 42.2 (2C). IR (neat): ~  = 3026 (w), 2995 (w, 2915 (w), 2854 (w), 2220 
(m), 1154 (s), 1483 (m), 1450 (w), 1400 (m), 1358 (m), 1330 (w), 1314 (w), 1281 (w), 1261 (w), 
1204 (s), 1163 (m), 1103 (w), 1004 (s), 994 (w), 949 (m), 939 (m), 877 (w), 788 (w), 763 (m), 952 
(m), 742 (s), 701 (w), 686 (s). HRMS (ESI): m/z calcd for C11H12NO2S [M + H]




(dimethylamino)ethoxy)(phenyl)methyl)phenyl)-3,3-diphenylpropan-2-one (27). Under 
nitrogen, a J-Young Schlenck tube was charged with XPhos (21 mg, 0.044 mmol, 0.11 equiv), 
Pd2dba3 (18 mg, 0.02 mmol, 0.05 equiv) and Cs2CO3 (143.4 mg, 0.44 mmol, 1.1 equiv). 
Acetonitrile (0.4 mL) was then added and the mixture was stirred at room temperature for 10 
minutes. Then, bromazine (147 mg, 0.44 mmol, 1.1 equiv) was added in solution in acetonitrile 
(0.4 mL) followed by sulfoxonium ylide 43 (115 mg, 0.4 mmol, 1 equiv). The tube was then sealed, 
placed in a preheated oil bath set at 80 °C and stirred for 13 hours. The crude was then filtered 
over celite at room temperature using dichloromethane to transfer all the material and for rinsing. 
After evaporation of all volatiles, purification by flash chromatography (silica gel, CH2Cl2/MeOH: 
95:5 to 85:15) afforded compound 27 (170 mg, 79%). Amorphous solid. 1H NMR (500 MHz, 
CDCl3): δ 7.38-7.31 (m, 4H), 7.30-7.25 (m, 3H), 7.27-7.19 (m, 4H), 7.18-7.13 (m, 6H), 7.08 (d, J 
= 8.2 Hz, 2H), 5.38 (s, 1H), 4.98 (s, 1H), 3.62 (t, J = 5.7 Hz, 2H), 3.45 (s, 6H), 2.69 (t, J = 5.8 Hz, 
2H), 2.34 (s, 6H). 13C{1H} NMR (125 MHz, CDCl3): δ 186.2, 141.8, 141.6, 141.0 (2C), 134.7 
(2C), 130.6, 128.8 (4C), 128.2 (2C), 127.9 (4C), 127.4, 126.9 (2C), 126.8 (2C), 126.0 (2C), 86.6, 
83.5, 66.8, 58.5, 57.4, 45.5 (2C), 42.5 (2C). IR (neat): ~  = 3416 (w), 3023 (w), 2971 (w), 2971 
(w), 2923 (w), 2820 (w), 2771 (w), 1599 (w), 1546 (s), 1493 (m), 1451 (m), 1406 (w), 1362 (w), 
1302 (w), 1266 (w), 1186 (s), 1165 (s), 1098 (m), 1073 (m), 1057 (m), 1021 (s), 971 (m), 935 (w), 
853 (w), 811 (w), 784 (w), 737 (m), 697 (s). HRMS (ESI): m/z calcd for C34H38NO3S [M + H]
+: 
540.2567; found: 540.2570. 
Tert-butyl (5-(dimethyl(oxo)-λ6-sulfaneylidene)-4-oxo-5-phenylpentyl)carbamate (29). Under 
nitrogen, a J-Young Schlenck tube was charged with XPhos (189 mg, 0.396 mmol, 0.11 equiv), 
Pd2dba3 (165 mg, 0.18 mmol, 0.05 equiv) and Cs2CO3 (1.29 g, 3.96 mmol, 1.1 equiv). Acetonitrile 
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(3.6 mL) was then added and the mixture was stirred at room temperature for 10 minutes. Then, 
bromobenzene (0.58 mL, 5.4 mmol, 1.5 equiv) was added followed by sulfoxonium ylide 28 (1.00 
g, 3.6 mmol, 1 equiv). The inner wall of the Schlenck tube was rinsed with acetonitrile (3.6 mL) 
and the tube was then sealed, placed in a preheated oil bath set at 80 °C and stirred for 15 hours. 
The crude was then filtered over celite at room temperature using dichloromethane to transfer all 
the material and for rinsing. After evaporation of all volatiles, purification by flash 
chromatography (silica gel, ethyl acetate/methanol: 95:5 to 9:1) afforded compound 29 (1.00 g, 
79%). Off-white solid. 1H NMR (500 MHz, CDCl3): δ 7.40-7.30 (m, 3H), 7.28-7.22 (m, 2H), 4.80 
(br s, 1H), 3.49 (s, 6H), 3.14-2.96 (m, 2H), 2.19 (t, J = 6.6 Hz, 2H), 1.71 (q, J = 6.6 Hz, 2H), 1.41 
(s, 9H). 13C{1H} NMR (125 MHz, CDCl3): δ 188.2, 155.9, 134.6 (2C), 131.8, 128.6 (2C), 128.0, 
82.2, 78.7, 43.0 (2C), 40.4, 35.5, 28.4 (3C), 25.3; IR (neat): ~  = 3373 (m), 3019 (w), 2999 (w), 
2969 (w), 2949 (w), 2930 (w), 2867 (w), 1684 (s), 1557 (s), 1520 (s), 1489 (w), 1447 (w), 1439 
(w), 1409 (w), 1365 (m), 1346 (m), 1321 (w), 1290 (w), 1267 m), 1246 (s), 1189 (s), 1151 (s), 
1088 (w), 1063 (w), 1030 (s), 988 (s), 938 (w), 915 (w0, 863 (w), 791 (w), 781 (w), 771 (w), 758 




one (33). Obtained from 32 (132 mg, 0.4 mmol, 1 equiv) and bromobenzene (107 μL, 1 mmol, 2.5 
equiv) following the representative procedure and after difficult purification by flash 
chromatography (silica gel petroleum ether/ethyl acetate = 1:1 to 3:7) that led to a moderate yield 
despite a conversion of 73% determined by 1H NMR using 1,3,5-trimethoxybenzene as internal 
standard: 76 mg, 47%. White solid; m.p.: 145–147 °C. 1H NMR (500 MHz, CDCl3): δ 7.79 (s, 
2H), 7.69 (s, 1H), 7.31-7.23 (m, 3H), 7.19-7.13 (m, 2H), 3.64 (s, 6H). 13C{1H} NMR (125 MHz, 
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CDCl3): δ 178.4, 141.9, 134.7 (2C), 130.8, 130.7 (q, J = 33.2 Hz, 2C), 128.9* (q, J = 3.3 Hz, 2C), 
128.7 (2C), 128.2, 123.0 (q, J = 271.1 Hz, 2C), 122.6 (sept., J = 3.7 Hz), 88.3, 42.6 (2C) (the signal 
marked by an asterisk is an unresolved quartet; the coupling constant was determined from the two 
central resonances). 19F{1H} NMR (376 MHz, CDCl3):  δ -63.1. IR (neat): ~  = 3083 (w), 3040 
(w), 3023 (w), 2990 (w), 2914 (w), 1621 (w), 1523 (s), 1463 (w), 1436 (w), 1411 (m), 1348 (s), 
1304 (w), 1283 (s), 1274 (s), 1232 (s), 1197 (s), 1187 (s), 1169 (s), 1159 (m), 1120 (s), 1109 (s), 
1069 (w), 1012 (s), 984 (m), 961 (m), 935 (s), 905 (s), 876 (s), 843 (m), 773 (w), 753 (s), 699 (s), 
681 (s), 672 (m). HRMS (ESI): m/z calcd for C18H15F6O2S [M + H]
+: 409.0691; found: 409.0690. 
Iridium-catalyzed cyclization. Tert-butyl 3-oxo-2-phenylpiperidine-1-carboxylate (30). Under 
nitrogen, a J-Young Schlenck tube was charged with 29 (71 mg, 0.2 mmol, 1 equiv) and 
[Ir(cod)Cl]2 (3.4 mg, 0.005 mmol, 2.5 mol%). The tube was evacuated and refilled three times 
with nitrogen. 1,2-Dichloroethane (1.0 mL) was then added and the mixture was stirred at 80 °C 
overnight. After cooling down to room temperature, the reaction mixture was transferred to a round 
bottomed flask using dichloromethane to transfer all the material and for rinsing. After evaporation 
of all volatiles under vacuum, purification by flash chromatography (silica gel, petroleum 
ether/ethyl acetate: 90:10 to 85:15) afforded compound 30 (40 mg, 73%. Colorless oil. 1H NMR 
(500 MHz, CDCl3): δ 7.35 (t, J = 7.4 Hz, 2H), 7.31-7.26 (m, 1H), 7.21 (d, J = 7.6 Hz, 2H), 5.64  
(br s, 1H), 4.08 (br s, 1H), 3.39-3.24 (m, 1H), 2.53-2.37 (m, 2H), 2.01-1.83 (m, 2H), 1.43 (s, 9H), 
in agreement with previously reported data.57 
Synthesis of complex 37. This complex was prepared in three steps. First, following the procedure 
described by Gómez-Ruiz and co-workers,58 PdCl2 (2.00 g, 11.3 mmol, 1 equiv) was dissolved in 
37% HCl (12 mL) in a round-bottomed flask opened to air. The mixture was stirred until it cooled 
to room temperature and was then diluted with ethanol (226 mL) and filtered. The residue was 
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washed with ethanol (2  10 mL). Then, 1,5-cyclooctadiene (3.3 mL, 27.1 mmol, 2.4 equiv) was 
added while stirring, which triggered the immediate formation of a yellow precipitate. The reaction 
was allowed to stir for another 20 minutes. The solid was then filtered, washed with Et2O (2  20 
mL) and dried under high vacuum to afford dichloro(1,5-cyclooctadiene)palladium (3.07 g, 95%, 
yellow solid) which was used in the next step without further purification. Second, following the 
procedure described by Skrydstrup and co-workers,59 dichloro(1,5-cyclooctadiene)palladium 
(2.00 g, 7 mmol, 1 equiv) was suspended in Et2O (35 mL) in a flame-dried round bottom flask 
under nitrogen. The reaction was cooled to 0 °C and (trimethylsilyl)methylmagnesium chloride (1 
M in Et2O, 21 mL, 21.0 mmol, 3 equiv) was added dropwise over 10 minutes via syringe. The 
reaction was stirred at 0 °C for another 20 min. The reaction was quenched with acetone (1 mL). 
All volatiles were removed under high vacuum at 0 °C. The flask was then open to air. The residue 
was triturated with pentane (70 mL) at 0 °C. After filtration on celite, the filtrate was recovered 
into an ice-cooled round-bottomed flask and all volatiles were removed under vacuum at 0 °C. The 
flask containing the desired complex bis((trimethylsilyl)methyl)(1,5-cyclooctadiene)palladium 
(1.77 g, white solid, 65%) was transferred into an argon-filled glovebox for storage at -30 °C. The 
compound can be handled briefly at room temperature and is air stable, but decomposes at quickly 
at room temperature and turns black. The compound can be stored indefinitely at 0 °C or below. 
1H NMR (400 MHz, C6D6): δ 5.15 (s, 4H), 2.03-1.83 (m, 8H), 0.77 (s, 4H), 0.34 (s, 18H), in 
agreement with the previously reported data.60 Finally, using a modification of the procedure 
reported by Iwasawa and co-workers,48 a J-Young Schlenck tube was charged with 
Pd(cod)(CH2SiMe3)2 (195 mg, 0.5 mmol, 1 equiv) and XPhos (238 mg, 0.5 mmol, 1 equiv) in an 
argon-filled glovebox. The tube was sealed and taken out of the glovebox. Under N2, distilled 
cyclohexane (100 mL) and p-CF3C6H4Br (0.14 mL, 1 mmol, 2 equiv) were added. The tube was 
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sealed and the mixture was stirred at room temperature for 16 hours. Pentane (10 mL) was then 
added to the reaction which was then stirred slowly (ca 100 rpm) at -30 °C for 1 hour. The 
precipitate thus formed was filtered, washed with pentane (2  10 mL), and dried under high 
vacuum to afford 37 (126 mg, 31%). White solid. Crystals suitable for X-ray were obtained by 
slow evaporation over two weeks of a solution of complex 37 (10 mg) in CH2Cl2/hexane (1:2, 3 
mL). The 1H NMR (500 MHz, CDCl3) is complicated by a slow equilibration between 
conformers.61 19F{1H} NMR (376 MHz, CDCl3): δ -61.90 (s), -61.95 (br s), -62.8 (s); 
31P{1H} 
NMR (202 MHz, CDCl3): δ 57.6 (br), 28.7, 26.7; HRMS (ESI, MeCN): m/z calcd for C40H53F3PPd 
[M – Br]+: 727.2872; found: 727.2878. 
Synthesis of bromazine. A flame-dried round bottom flask was charged with 2-
(dimethylamino)ethan-1-ol (1.6 mL, 16 mmol, 2 equiv) in dry p-xylene (32 mL). 1-Bromo-4-
(bromo(phenyl)methyl)benzene (2.61 g, 8 mmol, 1 equiv) was then added in solution in p-xylene 
(8 mL) and the mixture was heated to reflux for 24 hours. The reaction mixture was then cooled 
to 0 °C and a saturated aqueous solution of Na2CO3 (50 mL) was carefully added. The aqueous 
layer was extracted with EtOAc (2  100 mL). The combined organic layers were washed with 
brine and dried with MgSO4. After filtration and evaporation of the solvent in vacuo, the crude 
product was purified by flash chromatography on silica gel (CH2Cl2/MeOH = 9:1) to afford 
bromazine (2.02 g, 76%, yellow oil). 1H NMR (500 MHz, CDCl3): δ 7.43 (d, J = 8.3 Hz, 2H), 
7.32-7.29 (m, 4 H), 7.27-7.20 (m, 3H), 5.31 (s, 1H), 3.55 (t, J = 6.0 Hz, 2H), 2.60 (t, J = 6.0 Hz, 
2H), 2.27 (s, 6H). 13C{1H} NMR (125 MHz, CDCl3): δ 141.7, 141.4, 131.4 (2C), 128.7 (2C), 128.5 
(2C), 127.6, 127.0 (2C), 121.2, 83.3, 67.6, 58.9, 46.0 (2C). IR (neat): ~  = 3026 (w), 2940 (w), 
2861 (w), 2817 (w), 2768 (w), 2449 (w), 1590 (w), 1485 (m), 1453 (m), 1397 (m), 1337 (w), 1295 
(w), 1184 (w), 1103 (s), 1070 (s), 1035 (s), 1010 (s), 957 (w), 930 (w), 889 (w), 794 (s), 748 (m), 
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The following files are available free of charge. 
Copies of NMR spectra of new compounds, data of kinetic experiments, ORTEP drawing of 
complex 37 (PDF) 
Crystallographic data for complex 37 (CIF) 
Accession Codes 
CCDC 1970048  contains the supplementary crystallographic data for this paper. These data can 
be obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif, or by emailimg data_request@ccdc.cam.ac.uk, or by 
contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, 
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